Phospho-BRCA1 (S1524) Antibody

What is Phospho-BRCA1 (S1524) and why is it important in research?

Phospho-BRCA1 (S1524) refers to the breast cancer 1 (BRCA1) protein that has been phosphorylated at serine residue 1524. BRCA1 is a 220 kDa nuclear phosphoprotein that plays critical roles in maintaining genomic stability and functions as a tumor suppressor. This specific phosphorylation site is particularly important because it is modified in response to DNA damage through ATR-dependent and Claspin-mediated pathways . The phosphorylation status at S1524 serves as a marker for BRCA1 activation during DNA damage response and transcriptional activation, making it valuable for understanding both normal cellular functions and disease mechanisms.

Research on Phospho-BRCA1 (S1524) is significant because BRCA1 mutations are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers . Understanding the role of this specific phosphorylation site helps elucidate BRCA1's functions in DNA repair, transcription regulation, and tumor suppression.

What are the key specifications of commercially available Phospho-BRCA1 (S1524) antibodies?

Commercial Phospho-BRCA1 (S1524) antibodies typically share several important specifications:

The antibodies are usually generated using a phospho-specific peptide corresponding to residues surrounding S1524 of human BRCA1 as the immunogen . They are designed to specifically recognize the phosphorylated form of BRCA1 at this residue without cross-reactivity to the non-phosphorylated form.

How does BRCA1 phosphorylation at S1524 relate to cell cycle regulation?

BRCA1 is a serine phosphoprotein that undergoes dynamic changes in phosphorylation status throughout the cell cycle. Research has demonstrated that BRCA1 undergoes hyperphosphorylation during late G1 and S phases of the cell cycle and is transiently dephosphorylated early after M phase .

While multiple phosphorylation sites exist on BRCA1, the S1524 site is particularly important for its functions. Phosphoamino acid analysis has revealed that BRCA1 is phosphorylated predominantly on serine residues (including S1524) and weakly on threonine residues . Two-dimensional tryptic peptide analysis has identified at least 13 tryptic peptides containing phosphoserine, indicating that BRCA1 is multiply phosphorylated .

This cell cycle-dependent phosphorylation pattern suggests that Phospho-BRCA1 (S1524) may play important regulatory roles during DNA replication and mitosis, potentially coordinating DNA repair with cell cycle progression.

What are the recommended protocols for detecting Phospho-BRCA1 (S1524) via Western blotting?

When detecting Phospho-BRCA1 (S1524) via Western blotting, researchers should follow these methodological guidelines:

• Sample Preparation:

  • Lyse cells in an appropriate buffer containing phosphatase inhibitors to prevent dephosphorylation.

  • Use freshly prepared samples when possible, as freeze-thaw cycles may affect phosphorylation status.

• Gel Electrophoresis:

  • Use lower percentage gels (6-8%) to properly resolve the 220 kDa BRCA1 protein.

  • Load adequate protein (50-100 μg per lane) to detect endogenous levels.

• Transfer and Blocking:

  • Perform overnight transfer at low voltage for high molecular weight proteins.

  • Block with 5% BSA in TBST rather than milk, as milk contains phosphatases.

• Primary Antibody Incubation:

  • Use Phospho-BRCA1 (S1524) antibody at a dilution of 1:1000 .

  • Incubate overnight at 4°C for optimal results.

• Detection and Controls:

  • Include positive controls (cells treated with DNA damaging agents) and negative controls.

  • Consider using total BRCA1 antibody on parallel blots to normalize phospho-signal.

When interpreting results, researchers should be aware that all BRCA1 antibodies may cross-react with other proteins, but in a fashion unique for each antibody . Therefore, careful validation of specificity is essential.

How can Cell-Based ELISA be used to quantify Phospho-BRCA1 (S1524) levels?

Cell-Based ELISA provides advantages over traditional Western blot analysis for quantifying Phospho-BRCA1 (S1524) levels, being more accurate, time-efficient, and scalable. The methodology involves:

• Cell Culture:

  • Cells are grown directly in 96-well microplates.

  • Treatments can be applied to stimulate or inhibit phosphorylation.

• Fixation and Permeabilization:

  • Cells are fixed to preserve phosphorylation status.

  • Permeabilization allows antibody access to intracellular targets.

• Antibody Incubation:

  • Anti-Phospho-BRCA1 (S1524) antibody is applied at appropriate dilution.

  • Anti-total BRCA1 antibody is used in parallel wells for normalization.

• Detection:

  • HRP-conjugated secondary antibody (anti-rabbit IgG) is applied.

  • One-Step TMB substrate is added for colorimetric detection .

• Normalization:

  • Crystal violet solution is used for cell number counts.

  • Results are normalized to cell number to adjust for plating differences .

This method enables high-throughput analysis of Phospho-BRCA1 (S1524) in response to various stimuli, providing quantitative data on phosphorylation status that can be measured using a standard ELISA plate reader .

How can researchers induce and monitor BRCA1 phosphorylation at S1524 in cell culture?

Researchers can employ several methods to induce and monitor BRCA1 phosphorylation at S1524:

Induction Methods:

• DNA Damage Agents:

  • Ionizing radiation activates ATM-mediated phosphorylation.

  • UV radiation triggers ATR-dependent phosphorylation.

  • Chemical agents like etoposide, camptothecin, or cisplatin induce DNA damage.

• Serum Stimulation:

  • Serum starvation followed by serum supplementation can induce BRCA1 phosphorylation during gene activation .

  • This approach is particularly useful for studying transcription-related roles.

• Cell Cycle Synchronization:

  • Synchronize cells at G0 phase by serum starvation.

  • Release into G1 phase to observe phosphorylation changes .

Monitoring Methods:

• Western Blotting:

  • Using Phospho-BRCA1 (S1524) specific antibodies at 1:1000 dilution .

  • Compare with total BRCA1 levels for relative quantification.

• Immunofluorescence:

  • Visualize subcellular localization of phosphorylated BRCA1.

  • Co-stain with markers of DNA damage response.

• Chromatin Immunoprecipitation (ChIP):

  • Detect phosphorylated BRCA1 at specific genomic loci.

  • ChIP-qPCR can be used to examine enrichment at transcription start sites of genes like JUN, FOS, MYC, and EGR1 .

• Cell-Based ELISA:

  • Quantify phosphorylation levels in response to various stimuli .

These approaches provide complementary information about the dynamics, localization, and function of Phospho-BRCA1 (S1524) in different cellular contexts.

What is the role of Phospho-BRCA1 (S1524) in transcriptional regulation?

Recent research has uncovered a novel function of Phospho-BRCA1 (S1524) in transcriptional regulation:

• Gene Activation Process:

  • BRCA1 is phosphorylated at S1524 by ATM and ATR kinases specifically during gene activation .

  • This phosphorylation event is crucial for productive transcription.

• Interaction with Transcriptional Machinery:

  • The BRCA1-BARD1 complex interacts with topoisomerase IIβ (TOP2B) at the transcription start site of EGR1 and numerous other protein-coding genes .

  • Phospho-BRCA1 (S1524) is enriched at the transcription start sites (TSSs) of immediate early genes (IEGs) including JUN, FOS, MYC, and EGR1 .

• Regulatory Mechanism:

  • The BRCA1-BARD1 complex ubiquitinates TOP2B, which stabilizes TOP2B binding to DNA.

  • BRCA1 phosphorylation at S1524 controls the TOP2B ubiquitination by the complex .

  • This process is essential for RNA polymerase II (Pol II)-dependent transcription in stimulus-inducible genes.

This research demonstrates that Phospho-BRCA1 (S1524) plays a critical role beyond DNA damage response, functioning as a regulator of stimulus-inducible transcriptional activation through modulation of topoisomerase IIβ activity. The phosphorylation at S1524 appears to be a key regulatory event that coordinates BRCA1's functions in both DNA repair and transcription.

How does the BRCA1-BARD1 complex function in relation to Phospho-BRCA1 (S1524)?

The BRCA1-BARD1 (BRCA1-associated ring domain 1) complex performs several critical functions that are influenced by BRCA1 phosphorylation at S1524:

• Complex Formation and Stability:

  • BRCA1 and BARD1 form a heterodimer with E3 ubiquitin ligase activity.

  • Phosphorylation at S1524 may influence the stability or activity of this complex.

• DNA Damage Response Integration:

  • The phosphorylation of BRCA1 at S1524 by ATM and ATR kinases links the BRCA1-BARD1 complex to DNA damage signaling pathways .

  • This phosphorylation likely regulates the complex's recruitment to sites of DNA damage.

• Transcriptional Regulation:

  • The BRCA1-BARD1 complex interacts with topoisomerase IIβ (TOP2B) at transcription start sites .

  • The complex ubiquitinates TOP2B, which stabilizes TOP2B binding to DNA.

  • Crucially, BRCA1 phosphorylation at S1524 controls the TOP2B ubiquitination by the complex .

• Genomic Surveillance:

  • The BRCA1-BARD1 complex is part of the larger BRCA1-associated genome surveillance complex (BASC) .

  • This complex integrates DNA damage sensors, tumor suppressors, and signal transducers to maintain genomic stability.

Research demonstrates that the regulatory relationship between Phospho-BRCA1 (S1524) and the BRCA1-BARD1 complex is bidirectional: the phosphorylation status influences complex activity, while the complex's interactions with other proteins can affect phosphorylation patterns. This relationship is particularly important during transcription-coupled DNA break repair and stimulus-inducible gene activation.

What is the significance of Phospho-BRCA1 (S1524) in DNA damage response pathways?

Phosphorylation of BRCA1 at S1524 plays a pivotal role in DNA damage response (DDR) pathways:

• Activation Mechanism:

  • In response to DNA damage, BRCA1 is phosphorylated at S1524 through ATR-dependent and Claspin-mediated recruitment .

  • This phosphorylation is primarily mediated by ATM and ATR kinases, connecting BRCA1 to the broader DNA damage sensing network .

• Spatiotemporal Regulation:

  • Phosphorylation at S1524 can be considered a signature DDR modification .

  • The timing of this phosphorylation may help coordinate various aspects of the damage response.

• Functional Consequences:

  • Phosphorylation at S1524 likely influences BRCA1's ability to participate in homologous recombination repair.

  • This modification may alter BRCA1's interactions with other DNA repair factors or change its subcellular localization.

• Integration with Cell Cycle Control:

  • Since BRCA1 undergoes hyperphosphorylation during late G1 and S phases , the S1524 phosphorylation may help synchronize DNA repair with cell cycle progression.

  • This coordination is critical for maintaining genomic stability during DNA replication.

The significance of this phosphorylation site is underscored by the fact that mutations in BRCA1 are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers . Understanding how phosphorylation at S1524 regulates BRCA1 function provides insights into both normal cellular processes and disease mechanisms.

How can researchers troubleshoot non-specific binding when using Phospho-BRCA1 (S1524) antibodies?

When working with Phospho-BRCA1 (S1524) antibodies, researchers may encounter non-specific binding issues. Here are methodological approaches to troubleshoot these problems:

• Antibody Validation:

  • Verify antibody specificity using positive and negative controls (e.g., BRCA1-depleted cells, phosphatase-treated samples).

  • Consider using multiple antibodies targeting different BRCA1 epitopes to confirm results.

• Addressing Known Cross-Reactivity:

  • Be aware that BRCA1 antibodies may cross-react with other proteins in a manner unique to each antibody .

  • For instance, C-terminal antibodies may detect a protein species of approximately 150 kDa predominantly found in membrane fractions, which could be the human epidermal growth factor receptor (EGFR) protein .

• Optimization Strategies:

  • Increase blocking time or concentration (5% BSA instead of 3%).

  • Add 0.1-0.5% Tween-20 to antibody dilution buffer.

  • Optimize antibody concentration through titration experiments.

  • Increase washing steps between antibody incubations.

• Sample Preparation Improvements:

  • Use phosphatase inhibitors to preserve phosphorylation status.

  • Consider subcellular fractionation to enrich for nuclear proteins, as BRCA1 is predominantly nuclear .

• Signal Verification:

  • Confirm signal specificity by phosphatase treatment of duplicate samples.

  • Use lambda phosphatase to remove phosphate groups and verify loss of signal.

By systematically addressing these aspects, researchers can improve the specificity of Phospho-BRCA1 (S1524) detection and generate more reliable data for their experiments.

How should phosphorylation at S1524 be analyzed in relation to other BRCA1 phosphorylation sites?

BRCA1 is a multiply phosphorylated protein with at least 13 tryptic peptides containing phosphoserine identified through two-dimensional peptide mapping . Analyzing S1524 phosphorylation in relation to other sites requires systematic approaches:

• Comprehensive Phosphorylation Analysis:

  • Phosphoamino acid analysis has shown that BRCA1 is phosphorylated predominantly on serine residues and weakly on threonine residues .

  • Consider mass spectrometry-based phosphoproteomic approaches to simultaneously monitor multiple phosphorylation sites.

• Methodological Integration:

  • Use site-specific phospho-antibodies to compare relative phosphorylation levels at different sites.

  • Apply phospho-specific ELISA to quantitatively measure multiple phosphorylation events.

  • Implement in vitro kinase assays to determine site-specific phosphorylation by different kinases.

• Temporal Analysis:

  • Monitor phosphorylation kinetics at S1524 and other sites during cell cycle progression and in response to DNA damage.

  • BRCA1 undergoes hyperphosphorylation during late G1 and S phases, followed by transient dephosphorylation after M phase .

• Functional Correlation:

  • Correlate S1524 phosphorylation with other phosphorylation events to identify synergistic or antagonistic relationships.

  • Use phospho-mimetic or phospho-deficient mutants to dissect the specific contributions of S1524 versus other sites.

• Interaction Network Analysis:

  • Determine how phosphorylation at S1524 affects BRCA1's interaction with the BARD1 complex compared to other phosphorylation events.

  • Investigate whether S1524 phosphorylation influences the recognition of BRCA1 by specific reader proteins distinct from other phosphorylation sites.

This integrated approach allows researchers to place S1524 phosphorylation within the broader context of BRCA1 regulation and function, providing insights into how multiple phosphorylation events coordinate BRCA1's diverse cellular roles.

What approaches can be used to validate the specificity of Phospho-BRCA1 (S1524) signal?

Validating the specificity of Phospho-BRCA1 (S1524) signal is crucial for obtaining reliable experimental results. Researchers should consider these methodological approaches:

• Genetic Validation:

  • Use BRCA1 knockout or knockdown systems to confirm absence of signal.

  • Employ CRISPR-Cas9 to generate S1524A mutants (non-phosphorylatable) to verify signal specificity.

  • Re-express wild-type versus S1524A mutant BRCA1 in BRCA1-deficient cells.

• Biochemical Validation:

  • Treat samples with lambda phosphatase to remove phosphate groups and confirm loss of signal.

  • Use competing phosphopeptides in blocking experiments to demonstrate antibody specificity.

  • Perform immunoprecipitation followed by mass spectrometry to verify the phosphorylation site.

• Physiological Validation:

  • Confirm expected changes in phosphorylation following known stimuli (e.g., DNA damage, serum stimulation).

  • Verify that ATM/ATR inhibitors prevent S1524 phosphorylation .

  • Demonstrate cell cycle-dependent changes in phosphorylation status .

• Technical Controls:

  • Use parallel detection of total BRCA1 to normalize phospho-specific signals.

  • Include positive controls (e.g., cells treated with DNA damaging agents) in each experiment.

  • Employ multiple detection methods (Western blot, ELISA, immunofluorescence) to corroborate results.

• Cross-Antibody Validation:

  • Use multiple antibodies against Phospho-BRCA1 (S1524) from different vendors or production lots.

  • Compare results with antibodies targeting nearby phosphorylation sites to establish specificity.

By implementing these validation approaches, researchers can ensure that their observed Phospho-BRCA1 (S1524) signal truly represents the biological phenomenon under investigation rather than technical artifacts or non-specific interactions.

How can Phospho-BRCA1 (S1524) antibodies be used in chromatin immunoprecipitation studies?

Chromatin immunoprecipitation (ChIP) using Phospho-BRCA1 (S1524) antibodies provides valuable insights into the genomic localization of phosphorylated BRCA1 and its role in transcriptional regulation:

• Experimental Design:

  • Use cell synchronization methods to capture specific cell cycle phases when BRCA1 hyperphosphorylation occurs .

  • Consider serum starvation (S0) followed by serum supplementation (S15) to induce BRCA1 phosphorylation during gene activation .

  • Include stimulus-inducible conditions to study Phospho-BRCA1 (S1524) recruitment to transcription start sites.

• Protocol Optimization:

  • Optimize crosslinking conditions to preserve protein-DNA interactions.

  • Use sonication parameters that generate 200-500 bp DNA fragments.

  • Implement stringent washing steps to reduce background.

  • Pre-clear chromatin with protein A/G beads to minimize non-specific binding.

• Data Analysis Approaches:

  • Perform ChIP-qPCR to examine enrichment at transcription start sites of known target genes like JUN, FOS, MYC, and EGR1 .

  • Consider ChIP-seq for genome-wide profiling of Phospho-BRCA1 (S1524) binding sites.

  • Analyze co-localization with TOP2B binding sites and RNA Polymerase II occupancy.

• Validation Strategies:

  • Perform sequential ChIP (re-ChIP) to determine co-occupancy with BARD1 or other factors.

  • Use BRCA1 S1524A mutants as negative controls.

  • Compare phospho-specific ChIP with total BRCA1 ChIP to determine phosphorylation-specific enrichment patterns.

• Functional Integration:

  • Correlate Phospho-BRCA1 (S1524) binding with gene expression data.

  • Investigate the relationship between Phospho-BRCA1 (S1524) occupancy and TOP2B-mediated DNA breaks during transcription.

  • Examine how ATM/ATR inhibition affects Phospho-BRCA1 (S1524) recruitment to chromatin.

These approaches enable researchers to elucidate the role of Phospho-BRCA1 (S1524) in chromatin-associated processes, particularly its function in regulating topoisomerase IIβ and RNA polymerase II-mediated gene expression .

What is the relationship between Phospho-BRCA1 (S1524) and cancer development or treatment?

Understanding the relationship between Phospho-BRCA1 (S1524) and cancer has important implications for both disease mechanisms and therapeutic strategies:

• Cancer Development:

  • Mutations in BRCA1 are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers .

  • Since S1524 phosphorylation is critical for BRCA1 function in DNA repair and transcription, defects in this phosphorylation event may contribute to genomic instability and cancer development.

  • The ATR-dependent phosphorylation of BRCA1 at S1524 links it to replication stress responses, which are often dysregulated in cancer cells.

• Biomarker Potential:

  • Phospho-BRCA1 (S1524) levels may serve as biomarkers for:

    • DNA damage response capacity

    • Cell cycle checkpoint functionality

    • Potential sensitivity to specific therapeutic agents

• Therapeutic Implications:

  • PARP inhibitors exploit synthetic lethality in BRCA1-deficient cells.

  • Understanding how S1524 phosphorylation affects BRCA1 function may reveal:

    • New therapeutic vulnerabilities

    • Mechanisms of resistance to existing therapies

    • Potential combination treatment strategies

• Research Directions:

  • Investigate how cancer-associated mutations affect BRCA1 phosphorylation at S1524.

  • Determine whether Phospho-BRCA1 (S1524) status correlates with response to chemotherapy or radiotherapy.

  • Explore whether targeting the kinases responsible for S1524 phosphorylation (ATM/ATR) could synergize with other cancer treatments.

• Clinical Applications:

  • Developing assays to measure Phospho-BRCA1 (S1524) in tumor samples may help guide treatment decisions.

  • Monitoring changes in Phospho-BRCA1 (S1524) during treatment could provide early indicators of treatment efficacy or resistance development.